A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003).
高悪性度の漿液性上皮卵巣、原発性腹膜、または以前のプラチナベースの化学療法の後に再発した卵管癌を持つ参加者の他の抗がんの治療剤の有無にかかわらず、ラルドタタグderuxtecanの安全性と有効性を評価するための第1B/2のオープンラベルの多施設研究
Researchers are looking for other ways to treat high-grade serous and certain other ovarian cancer. High-grade means the cancer cells grow and spread quickly. Serous means the cancer started in the cells that cover the ovaries, the lining of the belly, or in the fallopian tubes.
Standard treatment (usual treatment) for people with high-grade serous ovarian cancer may include:
- Chemotherapy, which is a treatment that uses medicine to destroy cancer cells or stop them from growing
- Targeted therapy, which is a treatment that works to control how specific types of cancer cells grow and spread
Raludotatug deruxtecan (R-DXd) is a study treatment that is an antibody drug conjugate (ADC). An ADC attaches to a protein on cancer cells and delivers treatment to destroy those cells. Researchers want to know if R-DXd is safe to take with other treatments and if people tolerate them together. They also want to learn how many people have the cancer respond (gets smaller or goes away) to the treatments.
調査の概要
状態
条件
詳細な説明
This study has 2 parts: Part 1 is a dose escalation phase of R-DXd. Part 2 is the expansion phase and will use the Recommended Phase 2 Dose (RP2D) of R-DXd determined in Part 1.
研究の種類
入学 (推定)
段階
- フェーズ2
- フェーズ 1
連絡先と場所
研究連絡先
- 名前:Toll Free Number
- 電話番号:1-888-577-8839
- メール:Trialsites@msd.com
研究場所
-
-
Connecticut
-
New Haven、Connecticut、アメリカ、06510
- 募集
- Yale-New Haven Hospital-Smilow Cancer Hospital at Yale-New Haven ( Site 0019)
-
コンタクト:
- Study Coordinator
- 電話番号:203-785-2404
-
-
Kentucky
-
Louisville、Kentucky、アメリカ、40202
- 募集
- The University of Louisville, James Graham Brown Cancer Center ( Site 0009)
-
コンタクト:
- Study Coordinator
- 電話番号:502-562-3429
-
-
Louisiana
-
Shreveport、Louisiana、アメリカ、71103
- 募集
- TRIALS 365 ( Site 0020)
-
コンタクト:
- Study Coordinator
- 電話番号:318-408-1198
-
-
Massachusetts
-
Boston、Massachusetts、アメリカ、02215
- 募集
- Dana-Farber Cancer Institute ( Site 0015)
-
コンタクト:
- Study Coordinator
- 電話番号:877-338-7425
-
-
New York
-
New York、New York、アメリカ、10065
- 募集
- Memorial Sloan Kettering Cancer Center ( Site 0003)
-
コンタクト:
- Study Coordinator
- 電話番号:212-639-2000
-
-
Oklahoma
-
Oklahoma City、Oklahoma、アメリカ、73104
- 募集
- OU Health University of Oklahoma Medical Center ( Site 7000)
-
コンタクト:
- Study Coordinator
- 電話番号:405-271-1112
-
-
Texas
-
Fort Worth、Texas、アメリカ、76104
- 募集
- Texas Oncology - DFW ( Site 8000)
-
コンタクト:
- Study Coordinator
- 電話番号:615-329-7430
-
Houston、Texas、アメリカ、77030
- 完了
- Houston Methodist Hospital ( Site 0010)
-
-
Utah
-
West Valley City、Utah、アメリカ、84119
- 募集
- START Mountain Region ( Site 0008)
-
コンタクト:
- Study Coordinator
- 電話番号:801-907-4750
-
-
Virginia
-
Charlottesville、Virginia、アメリカ、22908
- 募集
- University of Virginia Health System ( Site 0011)
-
コンタクト:
- Study Coordinator
- 電話番号:434-924-9333
-
-
-
-
-
Manchester、イギリス、M20 4BX
- 募集
- The Christie NHS Foundation Trust ( Site 0405)
-
コンタクト:
- Study Coordinator
- 電話番号:+441619187689
-
-
East Sussex
-
Brighton、East Sussex、イギリス、BN2 1ES
- 募集
- University Hospitals Sussex NHS Foundation Trust ( Site 0404)
-
コンタクト:
- Study Coordinator
- 電話番号:+44 01273 696 955
-
-
England
-
Fulham、England、イギリス、SW3 6JJ
- 募集
- Royal Marsden Hospital ( Site 0402)
-
コンタクト:
- Study Coordinator
- 電話番号:+442078118084
-
Sutton、England、イギリス、SM2 5PT
- 募集
- The Royal Marsden NHS Foundation Trust. ( Site 0403)
-
コンタクト:
- Study Coordinator
- 電話番号:+442078118084
-
-
London, City of
-
London、London, City of、イギリス、E1 1RD
- 募集
- Barts Health NHS Trust ( Site 0401)
-
コンタクト:
- Study Coordinator
- 電話番号:020 7377 7000
-
London、London, City of、イギリス、SE1 3SS
- 募集
- Guy s & St Thomas NHS Foundation Trust ( Site 0400)
-
コンタクト:
- Study Coordinator
- 電話番号:+44 020 7188 7188
-
-
-
-
-
Haifa、イスラエル、3109601
- 募集
- Rambam Health Care Campus ( Site 0202)
-
コンタクト:
- Study Coordinator
- 電話番号:972-4-7776234
-
Jerusalem、イスラエル、9103102
- 募集
- Shaare Zedek Medical Center ( Site 0201)
-
コンタクト:
- Study Coordinator
- 電話番号:+972-(0)2-6555424
-
Petah Tikva、イスラエル、4941492
- 募集
- Rabin Medical Center ( Site 0203)
-
コンタクト:
- Study Coordinator
- 電話番号:+97239378076
-
Ramat Gan、イスラエル、5265601
- 募集
- Sheba Medical Center ( Site 0200)
-
コンタクト:
- Study Coordinator
- 電話番号:972-3-5304498
-
-
-
-
Victoria
-
St Albans、Victoria、オーストラリア、3021
- 募集
- Western Health-Sunshine & Footscray Hospitals ( Site 1002)
-
コンタクト:
- Study Coordinator
- 電話番号:+61402775432
-
-
-
-
Ontario
-
Toronto、Ontario、カナダ、M5G 2M9
- 募集
- Princess Margaret Cancer Centre ( Site 0101)
-
コンタクト:
- Study Coordinator
- 電話番号:416-946-2818
-
-
Quebec
-
Montreal、Quebec、カナダ、H4A 3J1
- 募集
- McGill University Health Centre ( Site 0100)
-
コンタクト:
- Study Coordinator
- 電話番号:514-934-1934x31975
-
Montreal、Quebec、カナダ、H2X 0A9
- 募集
- Centre Hospitalier de l'Université de Montréal ( Site 0102)
-
コンタクト:
- Study Coordinator
- 電話番号:514-890-8000
-
-
-
-
-
Sankt Gallen、スイス、9000
- 募集
- HOCH Health Ostschweiz ( Site 0801)
-
コンタクト:
- Study Coordinator
- 電話番号:+41714941111
-
-
Canton of Basel-City
-
Basel、Canton of Basel-City、スイス、4031
- 募集
- University Hospital Basel-Gynecology & Gynecologic Oncology ( Site 0802)
-
コンタクト:
- Study Coordinator
- 電話番号:+41613284214
-
-
Canton of Vaud
-
Lausanne、Canton of Vaud、スイス、1011
- 募集
- CHUV (centre hospitalier universitaire vaudois) ( Site 0800)
-
コンタクト:
- Study Coordinator
- 電話番号:+41795567362
-
-
-
-
-
Barcelona、スペイン、08035
- 募集
- Hospital Universitari Vall d'Hebron-Departamento de Oncologia- VHIO ( Site 0300)
-
コンタクト:
- Study Coordinator
- 電話番号:+349325434528607
-
Madrid、スペイン、28041
- 募集
- Hospital Universitario 12 de Octubre ( Site 0304)
-
コンタクト:
- Study Coordinator
- 電話番号:+34913908626
-
Madrid、スペイン、28040
- 募集
- Hospital Universitario Fundación Jiménez Díaz-START Madrid-FJD ( Site 0303)
-
コンタクト:
- Study Coordinator
- 電話番号:34915504800 x2805
-
Málaga、スペイン、29010
- 募集
- Hospital Universitario Virgen de la Victoria ( Site 0306)
-
コンタクト:
- Study Coordinator
- 電話番号:+34951032508
-
-
Barcelona
-
L'Hospitalet de Llobregat、Barcelona、スペイン、08908
- 募集
- Institut Català d'Oncologia - L'Hospitalet ( Site 0302)
-
コンタクト:
- Study Coordinator
- 電話番号:+34932607744
-
-
Madrid
-
Majadhonda、Madrid、スペイン、28222
- 募集
- HOSPITAL UNIVERSITARIO PUERTA DE HIERRO MAJADAHONDA ( Site 0307)
-
コンタクト:
- Study Coordinator
- 電話番号:+34 911917358
-
-
Madrid, Comunidad de
-
Madrid、Madrid, Comunidad de、スペイン、28027
- 募集
- Clinica Universidad de Navarra ( Site 0301)
-
コンタクト:
- Study Coordinator
- 電話番号:+349135319207513
-
-
Valenciana, Comunitat
-
Valencia、Valenciana, Comunitat、スペイン、46014
- 募集
- Hospital General Universitario de Valencia ( Site 0305)
-
コンタクト:
- Study Coordinator
- 電話番号:+34 963187527
-
-
-
-
-
Taipei、台湾、100225
- 募集
- National Taiwan University Hospital ( Site 3001)
-
コンタクト:
- Study Coordinator
- 電話番号:+886223123456
-
Taoyuan、台湾、33305
- 募集
- Chang Gung Medical Foundation-Linkou Branch ( Site 3002)
-
コンタクト:
- Study Coordinator
- 電話番号:+88633281200
-
-
-
-
-
Seoul、韓国、03080
- 募集
- Seoul National University Hospital ( Site 2000)
-
コンタクト:
- Study Coordinator
- 電話番号:+82220723511
-
Seoul、韓国、03722
- 募集
- Severance Hospital, Yonsei University Health System ( Site 2002)
-
コンタクト:
- Study Coordinator
- 電話番号:+82222282230
-
Seoul、韓国、05505
- 募集
- Asan Medical Center ( Site 2003)
-
コンタクト:
- Study Coordinator
- 電話番号:+82230103646
-
Seoul、韓国、06351
- 募集
- Samsung Medical Center ( Site 2001)
-
コンタクト:
- Study Coordinator
- 電話番号:82234101382
-
-
Kyonggi-do
-
Goyang-si、Kyonggi-do、韓国、10408
- 募集
- National Cancer Center ( Site 2004)
-
コンタクト:
- Study Coordinator
- 電話番号:82319201760
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Has pathologically documented diagnosis of high-grade serous or high-grade endometrioid epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer
- Participants in Part 1 cohorts and Part 2 Cohort A-2 Arms 1, 2, and 3, Cohort B-2, and Cohort C-2 Arm 3: Has measurable disease per Response Evaluation Criteria In Solid Tumors 1.1
- Participants in Cohort A-1 Arms 2 and 3: Has relapsed disease after 1 to 3 prior lines of therapy and radiographic evidence of disease progression ≥6 months (≥180 days) after the last dose of platinum-based therapy (ie, platinum-sensitive disease)
- Participants in Cohort B-1 and Cohort B-2: Has relapsed disease after 1 to 3 prior lines of therapy and radiographic evidence of disease progression <6 months (<180 days) after the last dose of platinum-based therapy (ie, platinum-resistant disease). Participants must have received no more than 1 prior bevacizumab-containing systemic treatment regimen
- Participants in Cohort B-1, Cohort B-2, Cohort C-2 Arm 3, Cohort E-1 and if administering bevacizumab is planned in Cohort D or Cohort A-2 Arms 1, 2, or 3: Is a candidate for bevacizumab treatment
- Has provided tumor tissue for biomarker research (all cohorts)
- Has an Eastern Cooperative Oncology Group performance status of 0 to 1
- Participants in Cohort C-1, Cohort C-2 Arm 3, Cohort D, and Cohort E-1: Has relapsed disease after 1 prior line of therapy, radiographic evidence of disease progression ≥6 months (≥180 days) after the last dose of platinum-based therapy (ie, platinum-sensitive disease) and progressed during prior treatment with poly-ADP ribose polymerase inhibitor (PARPi) in the first-line setting
- Participants in Cohort A-2 Arms 1, 2, and 3: Has relapsed disease after 1 prior line of therapy and radiographic evidence of disease progression ≥6 months (≥180 days) after the last dose of platinum-based therapy (ie, platinum-sensitive disease)
- Participants in Cohort C-2 Arms 1 and 2: Has a new, histologically confirmed diagnosis of International Federation of Gynecology and Obstetrics Stage III or Stage IV epithelial ovarian cancer (high-grade serous or high-grade endometrioid), fallopian tube cancer, or primary peritoneal cancer that is non-homologous recombination deficiency-positive
- Participants in Cohort C-2 Arms 1 and 2: According to the investigator's assessment, PARPi first-line maintenance treatment for non- homologous recombination deficiency (HRD)-positive disease is not the preferred option for the participant
- Participants in Cohort C-2 Arms 1 and 2: According to the investigator's assessment, bevacizumab treatment for non-HRD-positive disease is not the preferred option for the participant
Exclusion Criteria:
- Has any of the following within 6 months before allocation/randomization: cerebrovascular accident, transient ischemic attack, or other arterial thromboembolic event
- Has uncontrolled or significant cardiovascular disease
- Has clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses including, but not limited to, any underlying pulmonary disorder, and any autoimmune, connective tissue, or inflammatory disorders with potential pulmonary involvement, or prior pneumonectomy
- Has ≥Grade 2 peripheral neuropathy
- Has received prior treatment with cadherin-6-targeted agents
- Has received prior systemic anticancer therapy including investigational agents within 4 weeks or 5 half-lives (whichever is shorter) before allocation
- Has received prior radiotherapy within 2 weeks of the start of study intervention, or has radiation-related toxicities, requiring corticosteroids
- Receives chronic steroid treatment
- Has known additional malignancy that is progressing or has required active treatment within the past 3 years
- Has known active CNS metastases and/or carcinomatous meningitis
- Has any history of interstitial lung disease (ILD)/pneumonitis irrespective of prior steroid use, current ILD, or suspected ILD, or ILD that cannot be ruled out by imaging at screening
- Has active infection requiring systemic therapy
- HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:非ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Cohort A-1 Arm 1 (R-DXd + Carboplatin Dose 1)
Participants receive escalating doses of intravenous (IV) raludotatug deruxtecan (R-DXd) in combination with carboplatin at Dose 1. Participants can receive up to a maximum of six 3-week cycles of carboplatin (approximately 4 months) and will receive raludotatug deruxtecan until disease progression or discontinuation. |
IV infusion on Day 1 of every 3-week cycle.
他の名前:
IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles. Includes 5-HT3 Serotonin Receptor Antagonist, NK-1 receptor antagonist, and corticosteroid, administered per protocol. |
|
実験的:Cohort A-1 Arm 2 (R-DXd + Paclitaxel)
Participants receive escalating doses of IV R-DXd in combination with paclitaxel. Participants can receive up to a maximum of six 3-week cycles of paclitaxel (approximately 4 months) and will receive R-DXd until disease progression or discontinuation. |
IV infusion on Day 1 of every 3-week cycle.
他の名前:
Includes 5-HT3 Serotonin Receptor Antagonist, NK-1 receptor antagonist, and corticosteroid, administered per protocol. IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles. |
|
実験的:Cohort A-1 Arm 3 (R-DXd + Carboplatin Dose 2)
Participants receive escalating doses of intravenous (IV) R-DXd in combination with carboplatin at Dose 2. Participants can receive up to a maximum of six 3-week cycles of carboplatin (approximately 4 months) and will receive R-DXd until disease progression or discontinuation. |
IV infusion on Day 1 of every 3-week cycle.
他の名前:
IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles. Includes 5-HT3 Serotonin Receptor Antagonist, NK-1 receptor antagonist, and corticosteroid, administered per protocol. |
|
実験的:Cohort B-1 (R-DXd + Bevacizumab)
Participants receive escalating doses of IV R-DXd in combination with bevacizumab until disease progression or discontinuation. |
IV infusion on Day 1 of every 3-week cycle.
他の名前:
Includes 5-HT3 Serotonin Receptor Antagonist, NK-1 receptor antagonist, and corticosteroid, administered per protocol. IV infusion on Day 1 of every 3-week cycle.
他の名前:
|
|
実験的:Cohort B-2 (R-DXd RP2D + Bevacizumab)
Participants with platinum-resistant recurrent ovarian cancer (PRROC) receive recommended Phase 2 dose (RP2D) of IV R-DXd in combination with bevacizumab until disease progression or discontinuation. |
IV infusion on Day 1 of every 3-week cycle.
他の名前:
Includes 5-HT3 Serotonin Receptor Antagonist, NK-1 receptor antagonist, and corticosteroid, administered per protocol. IV infusion on Day 1 of every 3-week cycle.
他の名前:
|
|
実験的:Cohort C-1 (R-DXd + Pembrolizumab)
Participants receive escalating doses of IV R-DXd in combination with pembrolizumab. Participants can receive up to a maximum of thirty-five 3-week cycles of pembrolizumab (approximately 2 years) and will receive R-DXd until disease progression or discontinuation. |
IV infusion on Day 1 of every 3-week cycle.
他の名前:
Includes 5-HT3 Serotonin Receptor Antagonist, NK-1 receptor antagonist, and corticosteroid, administered per protocol. IV infusion on Day 1 of every 3-week cycle for a maximum of 35 cycles. |
|
実験的:Cohort D (R-DXd +/- Bevacizumab)
Participants with platinum-sensitive recurrent ovarian cancer (PSROC) receive IV R-DXd in combination with or without bevacizumab until disease progression or discontinuation. |
IV infusion on Day 1 of every 3-week cycle.
他の名前:
Includes 5-HT3 Serotonin Receptor Antagonist, NK-1 receptor antagonist, and corticosteroid, administered per protocol. IV infusion on Day 1 of every 3-week cycle.
他の名前:
|
|
実験的:Cohort A-2 Arm 1 (R-DXd RP2D + Carboplatin +/- Bevacizumab)
Participants with PSROC will receive the RP2D of R-DXd in combination with a maximum of 6 cycles of carboplatin with or without bevacizumab, until disease progression or discontinuation. |
IV infusion on Day 1 of every 3-week cycle.
他の名前:
IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles. Includes 5-HT3 Serotonin Receptor Antagonist, NK-1 receptor antagonist, and corticosteroid, administered per protocol. IV infusion on Day 1 of every 3-week cycle.
他の名前:
|
|
実験的:Cohort A-2 Arm 2 (R-DXd RP2D + Paclitaxel +/- Bevacizumab)
Participants with PSROC will receive the RP2D of R-DXd in combination with a maximum of 6 cycles of paclitaxel with or without bevacizumab, until disease progression or discontinuation. |
IV infusion on Day 1 of every 3-week cycle.
他の名前:
Includes 5-HT3 Serotonin Receptor Antagonist, NK-1 receptor antagonist, and corticosteroid, administered per protocol. IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles. IV infusion on Day 1 of every 3-week cycle.
他の名前:
|
|
アクティブコンパレータ:Cohort A-2 Arm 3 (Platinum-Based Doublet Chemotherapy +/- Bevacizumab)
Participants with PSROC will receive one of 3 regimens of investigator's choice of platinum-based doublet chemotherapy with or without bevacizumab. Platinum-based doublet chemotherapy will be administered for maximum of 8 cycles. Bevacizumab can be administered until disease progression or discontinuation. |
IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles. IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles. IV infusion on Day 1 of every 3-week cycle.
他の名前:
IV injection on days 1 and 8 of each 3-week Cycle IV injection administered on Day 1 of each 4-week cycle
他の名前:
|
|
実験的:Cohort E-1 (R-DXd + MK-2010)
Participants receive escalating doses of IV R-DXd in combination with MK-2010. Participants can receive up to a maximum of thirty-five 3-week cycles of MK-2010 (approximately 2 years) and will receive R-DXd until disease progression or discontinuation. |
IV infusion on Day 1 of every 3-week cycle.
他の名前:
Includes 5-HT3 Serotonin Receptor Antagonist, NK-1 receptor antagonist, and corticosteroid, administered per protocol. IV infusion on Day 1 of every 3-week cycle |
|
実験的:Cohort C-2 Arm 1 (Carboplatin + Paclitaxel + Pembrolizumab → R-DXd + Pembrolizumab)
Participants will receive carboplatin (Dose 1 or Dose 2), paclitaxel (five 3-week cycles), and pembrolizumab during the induction phase. During the maintenance phase, participants will receive RP2D of IV R-DXd (up to 2 years; participants with PR or SD at 2 years may continue until disease progression) in combination with pembrolizumab (up to thirty-five 3-week cycles). |
IV infusion on Day 1 of every 3-week cycle.
他の名前:
IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles. IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles. IV infusion on Day 1 of every 3-week cycle for a maximum of 35 cycles. |
|
実験的:Cohort C-2 Arm 2 (Carboplatin + Paclitaxel)
Participants will receive carboplatin (Dose 1 or Dose 2) and paclitaxel (seven 3-week cycles), followed by standard of care observation. |
IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles. IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles. |
|
実験的:Cohort C-2 Arm 3 (R-DXd + Pembrolizumab + Bevacizumab)
Participants with PSROC will receive RP2D of R-DXd in combination with pembrolizumab (up to thirty-five 3-week cycles) and bevacizumab until progressive disease. |
IV infusion on Day 1 of every 3-week cycle.
他の名前:
IV infusion on Day 1 of every 3-week cycle.
他の名前:
IV infusion on Day 1 of every 3-week cycle for a maximum of 35 cycles. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Part 1: Number of Participants Who Experience a Dose-limiting Toxicity (DLT) Per Common Terminology Criteria for Adverse Events, Version 5.0 (CTCAE v5.0)
時間枠:Up to 21 days
|
DLTs are defined as toxicities during the DLT evaluation period that are assessed by the investigator to be possibly, probably, or definitely related to study treatment and include: Grade 4 thrombocytopenia of any duration or Grade 3 thrombocytopenia lasting ≥7 days; Grade 3 or higher thrombocytopenia associated with clinically significant bleeding; Grade 4 lymphocytopenia lasting ≥14 days; Grade 4 anemia of any duration; any other Grade 4 hematologic toxicity lasting ≥7 days; febrile neutropenia Grade 3 or Grade 4 meeting pre-specifications; pre-specified hepatic organ toxicities; all Grade 3 or higher other nonhematologic toxicities except those pre-specified; other pre-specified nonhematologic toxicities; any delay in treatment with the planned dose of ≥21 days or discontinuation of treatment due to a toxicity during the DLT evaluation period, or Grade 5 toxicity. The number of participants with DLTs will be reported. |
Up to 21 days
|
|
Part 1: Number of Participants with One or More Adverse Events (AEs)
時間枠:Up to approximately 3 years
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants with one or more AEs will be reported. |
Up to approximately 3 years
|
|
Part 1: Number of Participants who Discontinue Study Intervention Due to an AE
時間枠:Up to approximately 3 years
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study intervention due to an AE will be reported. |
Up to approximately 3 years
|
|
Part 2: Objective Response Rate (ORR)
時間枠:Up to approximately 3 years
|
ORR is defined as the percentage of participants with Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1). The percentage of participants who experience CR or PR as assessed by Blinded Independent Central Review (BICR) will be presented. |
Up to approximately 3 years
|
|
Part 2: Progression Free Survival (PFS) - Cohort C-2 Arm 1 and Arm 2
時間枠:Up to approximately 3 years
|
PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first as assessed by Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1). PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS as assessed by blinded independent central review (BICR) will be presented. |
Up to approximately 3 years
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Part 1: Objective Response Rate (ORR)
時間枠:Up to approximately 3 years
|
ORR is defined as the percentage of participants who have a confirmed Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria In Solid Tumours version 1.1 (RECIST 1.1). ORR will be assessed by blinded independent central review (BICR). |
Up to approximately 3 years
|
|
Part 2: Duration of Response (DOR)
時間枠:Up to approximately 3 years
|
For participants who demonstrate a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1), DOR is defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. DOR as assessed by Blinded Independent Central Review (BICR) will be presented. |
Up to approximately 3 years
|
|
Part 2: PFS - Cohort A-2 Arm 2 and Arm 3
時間枠:Up to approximately 3 years
|
PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first as assessed by Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1). PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS as assessed by blinded independent central review (BICR) will be presented. |
Up to approximately 3 years
|
|
Part 2: Overall Survival (OS)
時間枠:Up to approximately 5 years
|
OS is defined as the time from the first dose of study treatment to death due to any cause. |
Up to approximately 5 years
|
|
Part 2: Number of Participants with One or More AEs
時間枠:Up to approximately 3 years
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study intervention due to an AE will be reported. |
Up to approximately 3 years
|
|
Part 2: Number of Participants who Discontinue Study Intervention Due to an AE
時間枠:Up to approximately 3 years
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study intervention due to an AE will be reported. |
Up to approximately 3 years
|
協力者と研究者
スポンサー
協力者
捜査官
- スタディディレクター:Medical Director、Merck Sharp & Dohme LLC
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- 5909-003
- MK-5909-003 (その他の識別子:MSD)
- U1111-1308-2821 (レジストリ識別子:UTN)
- 2024-514674-47-00 (レジストリ識別子:EU CT)
- REJOICE-Ovarian02 (その他の識別子:MSD)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。